Your browser doesn't support javascript.
loading
Case report: Characterization of the immunologic and molecular landscape in a unique presentation of invasive lobular carcinoma with concurrent uterine carcinosarcoma treated with immunotherapy.
Riedinger, Courtney J; Eisele, Caprice D; Esnakula, Ashwini; Stover, Daniel G; Freud, Aharon G; Cosgrove, Casey M.
Afiliación
  • Riedinger CJ; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, United States.
  • Eisele CD; The Ohio State University, Columbus, OH, United States.
  • Esnakula A; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Stover DG; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, United States.
  • Freud AG; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
  • Cosgrove CM; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, Columbus, OH, United States.
Front Immunol ; 15: 1422342, 2024.
Article en En | MEDLINE | ID: mdl-39076998
ABSTRACT
Invasive lobular breast cancer (ILC) is characterized by a relatively high risk for late recurrence and a unique metastatic pattern with an increased risk for metastasis to gynecologic organs and peritoneum. We present a unique case of recurrent ILC with metastasis to the abdominal peritoneum as well as the uterine myometrium and cervix. Treatment was complicated by the discovery of concomitant uterine carcinosarcoma. This patient was effectively treated with a combination of hormonal therapy for her metastatic ILC and a combination of chemotherapy and immunotherapy for uterine carcinosarcoma. Molecular evaluation revealed a characteristic CDH1 mutation within the ILC and a PI3KCA mutation within the uterine carcinosarcoma, both of which have been linked to epithelial-to-mesenchymal transitions. Examination of the tumor immune microenvironment revealed proportionally more cytotoxic NK cells. This robust immune infiltration may be an indicator of the response to immunotherapy observed in this tumor or a result of the metastatic breast cancer within the uterus. This report provides a characterization of the molecular and immunologic landscape in this case with metastatic ILC and uterine carcinosarcoma.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Uterinas / Neoplasias de la Mama / Carcinosarcoma / Carcinoma Lobular / Inmunoterapia Límite: Female / Humans / Middle aged Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Uterinas / Neoplasias de la Mama / Carcinosarcoma / Carcinoma Lobular / Inmunoterapia Límite: Female / Humans / Middle aged Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos